• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Technical Officer Shukla Abhinav A. exercised 12,563 shares at a strike of $3.57 and sold $2,874 worth of shares (410 units at $7.01) as part of a pre-agreed trading plan, increasing direct ownership by 14% to 98,533 units (SEC Form 4) to satisfy withholding obligation

    7/7/26 7:00:06 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $STTK alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Shukla Abhinav A.

    (Last)(First)(Middle)
    C/O SHATTUCK LABS, INC.
    500 W. 5TH STREET, SUITE 1200

    (Street)
    AUSTIN TEXAS 78701

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Shattuck Labs, Inc. [ STTK ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Technical Officer
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    07/02/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock07/02/2026M410A$3.5786,790D
    Common Stock07/02/2026S(1)410D$7.01(2)86,380D
    Common Stock07/06/2026M12,153A$3.5798,533D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Stock Option (Right to Buy)$3.5707/02/2026M410 (3)01/25/2033Common Stock410$0.0026,293D
    Stock Option (Right to Buy)$3.5707/06/2026M12,153 (3)01/25/2033Common Stock12,153$0.0014,140D
    Explanation of Responses:
    1. Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026. The plan is intended to execute sales of shares received upon option exercise only as needed to fund the exercise price and estimated tax withholding associated with option exercises under the plan. Under the procedures of the administering broker, acquired shares are first sold to fund the aggregate exercise price and estimated tax withholding with respect to all possible option exercises in a particular order under the plan and only once fully funded will acquired shares be held by the Reporting Person. This transaction represents the final sale of shares needed to fully fund the exercise price and estimated tax withholding for the option exercises under this order of the plan and the remaining shares acquired upon exercise under this order will be held by the Reporting Person.
    2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.000 to $7.030, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
    3. This option represents a right to purchase a total of 52,200 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer.
    /s/ Andrew R. Neill, Attorney-in-fact for Abhinav A. Shukla07/07/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $STTK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STTK

    DatePrice TargetRatingAnalyst
    7/20/2026$16.00Outperform
    Leerink Partners
    4/27/2026Overweight
    Cantor Fitzgerald
    3/6/2026$25.00Buy
    Needham
    1/28/2026$15.00Overweight
    Piper Sandler
    12/1/2025$6.00Neutral → Buy
    H.C. Wainwright
    9/8/2025$4.00Outperform
    Wedbush
    3/17/2025$4.00Outperform
    Leerink Partners
    10/2/2024$8.00 → $2.00Buy → Neutral
    Citigroup
    More analyst ratings

    $STTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Siegall Clay B bought $250,000 worth of shares (62,500 units at $4.00), increasing direct ownership by 24% to 318,608 units (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    6/11/26 5:00:03 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $5,471,826 worth of shares (6,306,127 units at $0.87) (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    9/2/25 9:52:10 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ashiya Mona bought $5,471,826 worth of shares (6,306,127 units at $0.87) (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    9/2/25 9:50:52 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technical Officer Shukla Abhinav A. exercised 12,563 shares at a strike of $3.57 and sold $2,874 worth of shares (410 units at $7.01) as part of a pre-agreed trading plan, increasing direct ownership by 14% to 98,533 units (SEC Form 4) to satisfy withholding obligation

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    7/7/26 7:00:06 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Technical Officer Shukla Abhinav A. exercised 23,465 shares at a strike of $3.57 and sold $166,131 worth of shares (23,465 units at $7.08) as part of a pre-agreed trading plan (SEC Form 4) (for tax liability)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    7/2/26 8:17:03 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Pandite Arundathy N. sold $210,300 worth of shares (30,000 units at $7.01) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 136,219 units (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    7/2/26 8:15:04 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Shattuck Labs with a new price target

    Leerink Partners initiated coverage of Shattuck Labs with a rating of Outperform and set a new price target of $16.00

    7/20/26 8:58:42 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Shattuck Labs

    Cantor Fitzgerald initiated coverage of Shattuck Labs with a rating of Overweight

    4/27/26 8:21:48 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham resumed coverage on Shattuck Labs with a new price target

    Needham resumed coverage of Shattuck Labs with a rating of Buy and set a new price target of $25.00

    3/6/26 8:36:02 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Shattuck Labs Inc.

    SCHEDULE 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

    7/17/26 9:30:07 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Shattuck Labs Inc.

    SCHEDULE 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

    6/15/26 6:10:16 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Shattuck Labs Inc.

    SCHEDULE 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

    6/11/26 9:00:20 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

    AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price per share of $4.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,870,624 shares of its common stock at a public offering price of $3.9999 per pre-funded war

    6/10/26 12:21:32 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs, Inc. Announces Proposed Public Offering

    AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has commenced a public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Shattuck expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its com

    6/9/26 4:18:28 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update

    AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced it has received notices to exercise totaling approximately 50.6 million common stock warrants to date, representing approximately 96% of the warrants issued in the Company's August 4, 2025 private placement. The exercise of these warrants is expected to result in aggregate gross proceeds of approximately $54.9 million. As of March 31, 2026, the

    6/9/26 8:00:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Financials

    Live finance-specific insights

    View All

    Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

    – Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks; further development of SL-172154 discontinued –   – Prioritization to focus on SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A, intended for clinical development in inflammatory bowel disease (IBD); IND filing expected in Q3 2025 – – SL-172154 associated restructuring expected to extend cash runway into 2027 – – Company to host investor call today at 8:00 AM Eastern Time (ET) – AUSTIN, T

    10/1/24 6:30:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

    – Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached – – Observed 43% ORR in frontline TP53m AML patients, 33% CR/complete remission with incomplete hematologic recovery (CRi) and median overall survival had not yet been reached – – SL-172154 demonstrated a manageable interim safety profile in combination with AZA – – Focuses clinical development opportunity in HR-MDS and TP53m AML; these indications may offer the fastest path to potential approval; enrollment underway in randomized, controlled HR-MDS co

    6/14/24 6:00:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

    - Conference call and webcast to be held June 14, 2024 at 7:30 a.m. ET featuring lead investigator - AUSTIN, TX and DURHAM, NC, June 06, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will host an investor call for an interim safety and efficacy update from the Phase 1B dose expansion clinical trial of SL-172154 with AZA in HR-MDS and TP53m AML, being presented at the EHA 2024 Congress. The event will feature lead investigator, Dr. Naval G. Dave

    6/6/24 7:30:00 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Leadership Updates

    Live Leadership Updates

    View All

    Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

    AUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors, effective March 1, 2024. Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck. "It is a pleasure to welcome Clay and Kate, esteemed industry leaders, to our Board of Directors," said Taylor Schre

    3/4/24 7:00:00 AM ET
    $IMNM
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023

    AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its third-quarter 2023 financial results and provide a general business overview on Thursday, November 9, 2023. Title: Shattuck Labs Third-Quarter 2023 Earnings Call Speakers: Taylor Schreiber, CEO; Andrew Neill, CFO; Lini Pandite, CMO Date & Time: Thursday, November 9, 2023 at 8:00 a.m. ET Dial-in Details: Toll-Free Dial-In Number: 1 (888) 440-4368 To

    11/6/23 9:28:40 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Announces Changes to its Board of Directors

    AUSTIN, TX and DURHAM, NC, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced the appointment of Dr. Carrie Brownstein, M.D., to its Board of Directors. Dr. Brownstein currently serves as the Chief Medical Officer at Cellectis. She will replace Josiah Hornblower, Shattuck's Chairman and founder, who is stepping down from the Board of Directors. George Golumbeski, Ph.D., has been appointed Chairman of the

    10/28/21 4:30:00 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Shattuck Labs Inc.

    SC 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

    12/6/24 9:03:38 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

    SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)

    11/13/24 8:30:26 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Shattuck Labs Inc.

    SC 13G/A - Shattuck Labs, Inc. (0001680367) (Subject)

    11/12/24 5:01:20 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care